Lyra Therapeutics (LYRA) CEO returns 2,000 shares to issuer

Rhea-AI Filing Summary

Lyra Therapeutics director and Principal Executive Officer Maria Palasis reported returning 2,000 shares of Common Stock to the company in a disposition to the issuer at $0.00 per share. After this transaction, she directly owns 1,094,733 shares, indicating only a small portion of her holdings was affected.

Insider Trade Summary 10b5-1

1 transaction reported

Mixed 1 txn

Insider Palasis Maria

Role Principal Executive Officer

Type	Security	Shares	Price	Value
Disposition	Common Stock	2,000	$0.00	--

Holdings After Transaction: Common Stock — 1,094,733 shares (Direct)

Footnotes (1)

Key Figures

Shares disposed: 2,000 shares Disposition price: $0.00 per share Shares owned after transaction: 1,094,733 shares

3 metrics

Shares disposed 2,000 shares Disposition to issuer of Common Stock

Disposition price $0.00 per share Price reported for 2,000-share disposition

Shares owned after transaction 1,094,733 shares Direct Common Stock holdings after Form 4 transaction

Key Terms

Disposition to issuer, Common Stock, Form 4

3 terms

Disposition to issuer financial

"transaction_code_description": "Disposition to issuer""

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Palasis Maria

(Last) (First) (Middle)

C/O LYRA THERAPEUTICS, INC.

480 ARSENAL WAY

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyra Therapeutics, Inc. [ LYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		D		2,000	D	$0	1,094,733	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jason Cavalier, Attorney-in-Fact for Maria Palasis, Ph.D.	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Lyra Therapeutics (LYRA) report for Maria Palasis?

Lyra Therapeutics reported that Maria Palasis disposed of 2,000 shares of Common Stock in a transaction categorized as a disposition to the issuer. This means the shares were returned to the company rather than sold on the open market.

How many Lyra Therapeutics (LYRA) shares does Maria Palasis hold after this Form 4?

Following the reported transaction, Maria Palasis directly holds 1,094,733 shares of Lyra Therapeutics Common Stock. The 2,000 shares returned to the issuer represent a small change relative to her remaining direct ownership position.

At what price were the 2,000 Lyra Therapeutics (LYRA) shares disposed of?

The 2,000 shares of Lyra Therapeutics Common Stock were disposed of at a reported price of $0.00 per share. This zero per-share value is consistent with a disposition to the issuer rather than an open-market sale for cash proceeds.

What does 'disposition to issuer' mean in the Lyra Therapeutics (LYRA) Form 4?

A disposition to issuer indicates shares were transferred back to Lyra Therapeutics itself, not sold on an exchange. This type of transaction often reflects administrative or corporate actions instead of a market trade between the insider and public investors.

What is Maria Palasis’s role at Lyra Therapeutics (LYRA) mentioned in the filing?

The filing identifies Maria Palasis as both a director and the Principal Executive Officer of Lyra Therapeutics. Her Form 4 therefore reflects transactions by a senior executive with significant leadership responsibilities at the company.